About NADH dehydrogenase (ubiquinone) complex I, assembly factor 6
NADH dehydrogenase (ubiquinone) complex I, assembly factor 6 (NDUFAF6) is a protein
from Homo sapiens identified by UniProt accession
Q330K2, 333 residues long.
MolForge cross-references it against 0 known binders and
80 disease associations.
Target properties
| Protein name | NADH dehydrogenase (ubiquinone) complex I, assembly factor 6 |
| UniProt accession | Q330K2 |
| Gene | NDUFAF6 |
| Organism | Homo sapiens |
| Length | 333 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (80)
Diseases linked to this target (Open Targets).
- Leigh syndrome · score 0.69
- mitochondrial complex I deficiency · score 0.67
- genetic disorder · score 0.48
- neurodegenerative disease · score 0.48
- erythrocyte count · score 0.37
- Fanconi renotubular syndrome 1 · score 0.37
- urate measurement · score 0.36
- primary Fanconi syndrome · score 0.34
- hemoglobin measurement · score 0.33
- diastolic blood pressure · score 0.33
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q330K2-F1 | alphafold | PREDICTED | 86.53 | — |
Amino-acid sequence (333 residues)
MAASAHGSVW GPLRLGIPGL CCRRPPLGLY ARMRRLPGPE VSGRSVAAAS GPGAWGTDHY CLELLRKRDY EGYLCSLLLP AESRSSVFAL RAFNVELAQV KDSVSEKTIG LMRMQFWKKT VEDIYCDNPP HQPVAIELWK AVKRHNLTKR WLMKIVDERE KNLDDKAYRN IKELENYAEN TQSSLLYLTL EILGIKDLHA DHAASHIGKA QGIVTCLRAT PYHGSRRKVF LPMDICMLHG VSQEDFLRRN QDKNVRDVIY DIASQAHLHL KHARSFHKTV PVKAFPAFLQ TVSLEDFLKK IQRVDFDIFH PSLQQKNTLL PLYLYIQSWR KTY
Explore NADH dehydrogenase (ubiquinone) complex I, assembly factor 6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets